Exhibit 2 Company Milestones-authorized for educator review

This document is authorized for educator review use only by Gregory Theyel, California State University – East Bay until May 2018. Copying or posting is an infringement of copyright.

Exhibit 2 Company Milestones

1996 Merger of Ciba-Geigy and Sandoz to create one of the largest healthcare companies

2002 Novartis Institutes for Biomedical Research (NIBR) is created, headquartered in the United States

2003 Acquisition of Mead Johnson & Co., a subsidiary of Bristol-Myers Squibb

2004 Novartis submits Xolair for EU approval for treatment of allergic asthma

NIBR announces joint project with the Broad Institute of MIT and Harvard to research type 2 diabetes

2005 Landmark trial on Gleevec/Glivec, to treat chronic myeloid leukemia, shows 90% of patients still alive after four years of treatment

Aclasta gains EU regulation approval for treatment of Paget’s bone disease

Acquired North American over the counter brand portfolio of Bristol-Myers Squibb, expanding Novartis’ presence

2006 Strategic biomedical R&D center opens in Shanghai

Novartis Institute for Tropical Disease (NITD) initiates research on malaria. Through partnership with World Health Organization (WHO), provides anti-malarial Coartem, for no charge in developing nations

Omnitrope receives European Commission approval; 1st product approved under the EU’s new regulatory pathway for follow-on biological products

2007 Completed non-core divestments of the Gerber and Medical Nutrition Business units to Nestlé for $5.5 billion and $2.5 billion, respectively

Ranked No. 1 among pharmaceutical companies in Fortune magazine’s “World’s Most Admired Companies” survey

2008 Novartis announced an agreement to acquire 25% interest in Alcon, Inc., world leader in eye care with pharmaceutical, surgical, and consumer products (majority ownership acquired in 2010 and 100% in 2011)

Opened new vaccine research institute in Siena, Italy

Named healthcare super sector leader in the 2008 update of the Dow Jones Sustainability World Index

2009 Novartis became the first company to produce influence A (H1N1) vaccines with modern cell-culture biotechnology

Announced $1 billion investment over five years in China to build the largest pharmaceutical R&D institute in China

2010 Joseph Jimenez was named CEO

FDA approved Gilenya as the first oral treatment for relapsing-remitting multiple sclerosis

2011 Vaccines and medicines from Novartis reach an estimated $1 billion patients

Ranked No. 1 among pharmaceutical companies in Fortune magazine’s “World’s Most Admired Companies” survey

2012 Novartis to start construction of new biotechnology facility in Singapore with an investment of over $500 million

Source: Company documents.

Do N

ot C

op y

or P

os t

This document is authorized for educator review use only by Gregory Theyel, California State University – East Bay until May 2018. Copying or posting is an infringement of copyright. Permissions@hbsp.harvard.edu or 617.783.7860

Novartis: Leading a Global Enterprise 413-096

Exhibit 3 Divestments and Acquisitions, 1992–2012

Acquisitions Divestments Other 1992 Systemix (genetics science

company)

1994 Gerber (baby food producer), $3.7B

1995 Clariant (specialty chemicals) spun-off

1996 Azupharma (contract pharmaceutical developer)

MBT (construction chemicals) Novartis formed through merger of Ciba-Geigy and Sandoz Pharma divisions

1997 Merck Agro (crop protection business), $910M

Ciba non-pharmaceuticals businesses spun-off

First attempt U.S. listing (Delta) and integration of Stiftungen

1998 Roland

1999 Wasa sold to Barilla Alimentare ($315M), Eden sold to De-Vau- Ge Gesundkostwerk (undisclosed)

2000 Wesley Jessen VisionCare (contact lenses), $785M—made Ciba Vision the second-largest contact-lens company in the world

Syngenta (agribusiness) formed when Novartis and AstraZeneca PLC combined agricultural chemical business

2001 Roche (21.3%) (pharma)

2002 Roche (11.4%); Lek (generics), $900M

Wander AG (health foods)

2003 Unification of all generics operations into Sandoz

2004 Roche (0.6%); Sabex and Durascan; BMS medical nutrition

2005 Hexal; Eon Labs (generics); BMS over-the-counter

Nutrition & Santé (dietetics and organic foods) sold to ABN AMRO Capital France ($260M)

2006 Chiron (biotech firm), $5.4B Entry into human vaccines through Chiron acquisition

2007 Medical Nutrition business; Gerber baby foods sold to Nestlé ($5.5B)

2008 Speedel (pharmaceuticals), $880M

2009 Ebewe (injectables), $1.2B

2010 Merger with Alcon (eye care)

2012 Fougera Pharma for $1.25B

Source: Compiled from company documents.

Do N

ot C

op y

or P

os t

413-096 Novartis: Leading a Global Enterprise

Exhibit 4 Novartis Business Divisions

Division Name Description Pharmaceutical Products concentrated in major therapeutic areas including: primary care

(hypertension, metabolism, respiratory); established medicines (oncology, including hematology), specialty (neuroscience, ophthalmics, integrated hospital care, and critical care.) The portfolio included more than 40 key marketed products, many of which were leaders in their respective therapeutic areas. In 2011, the division received a total of 15 approvals in the United States, Europe and Japan. The product development pipeline had 138 projects in various stages of clinical development, including potential new products as well as potential new indications or formulations for existing products.

Alcon Alcon was the global leader in eye care with a breadth of product offerings in

surgical, ophthalmic pharmaceuticals and vision care, serving the full life cycle of patient needs across eye diseases and vision conditions.

Sandoz Sandoz develops, produces and markets approximately 1 000 compounds

across all major therapeutic areas, as well as biopharmaceuticals, active substances and intermediates. Its operations span five continents, and it markets products in about 130 countries. In addition to its retail generics business, Sandoz also operates anti-infectives and biopharmaceuticals and oncology injectables businesses, where it has a strong leadership position.

Consumer Health Novartis OTC (Over-the-Counter) was a world leader in the research,

development, production and marketing of self-care products designed for in- home treatment of medical conditions and ailments. The division had a portfolio of cough, cold, respiratory disease treatments, digestive health solutions and pain management medication, as well as skin care products, smoking- cessation therapies and mineral supplements. Novartis Animal Health was a leader in developing new and better ways to prevent and treat diseases in pets, farm animals and cultivated fish.

Vaccines and Diagnostics The Novartis Vaccines and Diagnostics Division provided more than 20

vaccines to prevent viral and bacterial diseases, as well as sophisticated instruments, assays and software to protect the blood supply from infectious diseases such as HIV and Hepatitis. The division consisted of two businesses—Novartis Vaccines and Novartis Diagnostics.

Source: Company documents.

Do N

ot C

op y

or P

os t

Novartis: Leading a Global Enterprise 413-096

Exhibit 5 Novartis Share Price vs. Indices, January 1997–January 2013

Source: Thomson Reuters Datastream, accessed May 7, 2013.

100

150

200

250

300

Ja nu

ar y

31 , 1

99 7

= 10

Novartis Relative Stock Price Performance January 1997 – January 2013

WORLD PHARMA INDEX NOVARTIS NOVARTIS ADR

Do N

ot C

op y

or P

os t

413-096 Novartis: Leading a Global Enterprise

Exhibit 6 Organizational Structure, January 2013

Source: Company documents. Information as of January 2013.

Audit & Compliance

Peter Elam

Corporate Secretary

Dr. Charlotte Pamer-Wieser

Human Resources

Dr. Jurgen Brokatzky-Geiger

General Counsel

Dr. Felix Ehrat

Strategic Planning & External Affairs

N.N.

CFO

Jon Symonds

Group Communications

Michele Galan

Chairman Audit & Compliance Committee

Prof. Srikant Datar

Group QA

Dr. Erwin Vanhaecke

Chairman Board of Directors

Prof. Ulrich Lehner

CEO

Joseph Jimenez

Chairman’s Office

Dr. Matthias Leuenberger

NIBR

Dr. Mark Fishman

Pharma

David Epstein

Sandoz

Jeff George

V&D

Dr. Andrin Oswald

Chief Compliance Officer

Dr. Peter Kornicker

ECN Members

Alcon

Kevin Buehler

OTC

Brian McNamara

Animal Health

Dr. George Gunn

Do N

ot C

op y

or P

os t

Novartis: Leading a Global Enterprise 413-096

Exhibit 7 Executive Committee, Select Years

Position 1997 2002 2007 2012 CEO, Novartis AG Daniel Vasella, M.D Daniel Vasella, M.D Daniel Vasella, M.D Joseph Jimenez

CFO, Novartis AG Raymund Breu, Ph.D Raymund Breu, Ph.D Raymund Breu, Ph.D. Jonathan Symonds

Head, Pharma Thomas Ebeling Joseph Jimenez David Epstein

Head, Consumer Health Paul Choffat, J.D Thomas Ebeling Brian McNamara

Head, Sandoz Andreas Rummelt, Ph.D. Jeff George

Head, Vaccines and Diagnostics

Joerg Reinhardt, Ph.D. Andrin Oswald

Head, Research Mark C. Fishman, M.D. (Pharma)

Mark C. Fishman, M.D.(biomedical)

Mark C. Fishman

Head, Human Resources Norman C. Walker Juergen Brokatzky-Geiger, Ph.D

Juergen Brokatzky- Geiger

Head, Legal and General Affairs

Alexandre Jetzer Urs Bärlocher J.D. Felix Ehrat, Ph.D

Head, Corporate Affairs Thomas Wellauer, Ph.D.

Head, Strategic Planning Gilbert Wenzel

Source: Company documents.

Exhibit 8 Novartis Board of Directors, 2012

Daniel Vasella, M.D.——Chairman

Ulrich Lehner, Ph.D.——Vice Chairman (since 2002) Former CEO, A.G.

Dimitri Azar, M.D., MBA (since 2012) Dean of the College of Medicine and Professor of Ophthalmology, Bioengineering and Pharmacology at the University of Illinois at Chicago.

William Brody, M.D., Ph.D. (since 2009) President of the Salk Institute for Biological Studies, La Jolla, California, and former president of Johns Hopkins.

Srikant Datar, Ph.D (since 2003) Professor at Harvard Business School.

Ann Fudge (since 2008) Former CEO of Young and Rubicam.

Pierre Landolt, Ph.D (since 1996) Chair of the Sandoz Family Foundation.

Enrico Vanni, Ph.D (since 2011) Former McKinsey Managing Partner.

Andreas von Planta, Ph.D (since 2006) Vice Chairman of Holcim Ltd. and of the Schweizerische National- Versicherungs-Gesellschaft A.G.

Dr. Ing. Wendelin Wiedeking (since 2003) Former CEO, Porsche, GmbH.

Margorie Mun Tak Yang (since 2008) Chairman of Esquel Group, Hong Kong, China.

Rolf M. Zinkernagel, M.D. (since 1999) University of Zurich Medical School Faculty and Nobel Prize Winner.

Source: Company documents.

Do N

ot C

op y

or P

os t

41 3-

09 6

-2

Ex hi

bi t 9

In -M

ar ke

t a nd

in P

ip el

in e

Ph ar

m a

Pr od

uc ts

, e ar

ly 2

01 3

ur ce

: C

om pa

ny d

oc um

en ts

. I nf

or m

at io

n as

o f e

ar ly

2 01

Do N

ot C

op y

or P

os t

Novartis: Leading a Global Enterprise 413-096

Exhibit 10 Average Annual Peak Sales of First Launched Products, 2007–2011 (in $ billions)

Source: Company documents.

Do N

ot C

op y

or P

os t

413-096 Novartis: Leading a Global Enterprise

Endnotes

1 “FTC Clears Novartis Merger, Creating the World’s Leading Life Sciences Company,” PR Newswire December 17, 1996, via Factiva, accessed March 2013. 2 McKinsey & Company, “An interview with Daniel Vasella,” September 2012, http://www.mckinsey.com/features/leading_in_the_21st_century/daniel_vasella, accessed March 2013. 3 Srikant Datar and Carin-Isabel Knoop, “Novartis (A): Being a Global Leader,” HBS No. 198-041. 4 Datar and Knoop. 5 Datar and Knoop. 6 Joseph Brown, “Concentrated focus (Novartis),” Med Ad News, September 1, 2000, via Factiva, accessed March 2013. 7 Brown. 8 “Agrochemical deal planted,” CNN Money, December 2, 1999, http://money.cnn.com/1999/12/02/europe/drugdeal/, accessed January 2013. 9 Brown. 10 Brown. 11 Brown. 12 Brown. 13 Kerry Capell, “Novartis: Radically Remaking Its Drug Business,” Bloomberg BusinessWeek, June 11, 2009, http://www.businessweek.com/magazine/content/09_25/b4136030131343.htm, accessed March 2013. 14 Capell. 15 Jeanne Whalen, “Novartis’s Big Experiment—Former Professor Reinvents Process for Making Drug Discoveries,” The Wall Street Journal, p. 4, January 19, 2005, via Factiva, accessed January 4, 2013. 16 Brown. 17 Moore. 18 Carey Sargent, “Novartis Can Stand Alone On Portfolio, Sales Strength,” Dow Jones International News, March 27, 2002, via Factiva, accessed March 22, 2013. 19 Nicolai Ouroussoff, “Many Hands, One Vision,” New York Times, December 23, 2009, http://www.nytimes.com/2009/12/27/arts/design/27novartis.html?pagewanted=all&_r=0, accessed April 2013. 20 Ouroussoff. 21 Haig Simonian, “Sandoz chief has no misgivings over Hexal,”Financial Times, April 13, 2005, http://search.proquest.com, accessed March 5, 2013. 22 “Novartis: Downgrade to Peer Perform after Alcon Acquisition,” Bear Stearns, April 8, 2008, available via Thomson ONE, accessed March 2013. 23 “Novartis: Downgrade to Peer Perform after Alcon Acquisition,” Bear Stearns, April 8, 2008. 24 McKinsey & Company, “An interview with Daniel Vasella,” September 2012, http://www.mckinsey.com/features/leading_in_the_21st_century/daniel_vasella, accessed March 4, 2013. 25 Geoff Colvin, “Novartis’s pathway to business longevity,” Fortune Magazine, March 21, 2013. 26 Colvin, “Novartis’s pathway to business longevity.” 27 Colvin, “Novartis’s pathway to business longevity.” 28 Colvin, “Novartis’s pathway to business longevity.” 29 Colvin, “Novartis’s pathway to business longevity.”

Do N

ot C

op y

or P

os t

Please follow and like us: